Related Experiment Video
Updated: Mar 28, 2026

06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Tumefactive demyelination presenting during bevacizumab treatment
Claire M Rice1, David Rossiter2, Janev Fehmi2
1Department of Neurology, North Bristol, NHS Trust Bristol, UK School of Clinical Sciences, University of Bristol, Bristol, UK.
BMJ Case Reports
|December 18, 2015
Abstract:
We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

